REN and chronic kidney disease: Recently, a prespecified analysis from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial demonstrated significantly reduced risk of chronic kidney disease progression in patients with IgAN treated with dapagliflozin added to renin-angiotensin-aldosterone system inhibitors.11